Literature DB >> 33170437

Germline BRCA-mutated metastatic breast cancer with positive hormone receptor.

Michela Palleschi1, Maria Laura Iaia1, Chiara Casadei2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33170437     DOI： 10.1007/s10549-020-06010-9

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN： 0167-6806            Impact factor:   4.872


× No keyword cloud information.
  2 in total

1.  Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.

Authors:  Patricia A Mote; Jennifer A Leary; Kelly A Avery; Kerstin Sandelin; Georgia Chenevix-Trench; Judy A Kirk; Christine L Clarke
Journal:  Genes Chromosomes Cancer       Date:  2004-03       Impact factor: 5.006

2.  Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.

Authors:  Susan M Domchek; Sophie Postel-Vinay; Seock-Ah Im; Yeon Hee Park; Jean-Pierre Delord; Antoine Italiano; Jerome Alexandre; Benoit You; Sara Bastian; Matthew G Krebs; Ding Wang; Saiama N Waqar; Mark Lanasa; Joon Rhee; Haiyan Gao; Vidalba Rocher-Ros; Emma V Jones; Sakshi Gulati; Anna Coenen-Stass; Iwanka Kozarewa; Zhongwu Lai; Helen K Angell; Laura Opincar; Pia Herbolsheimer; Bella Kaufman
Journal:  Lancet Oncol       Date:  2020-08-06       Impact factor: 41.316
  2 in total
  1 in total

Review 1.  Functional genomics for breast cancer drug target discovery.

Authors:  Tetsuro Yoshimaru; Yusuke Nakamura; Toyomasa Katagiri
Journal:  J Hum Genet       Date:  2021-07-20       Impact factor: 3.172
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.